Comparative safety of atypical antipsychotics and the risk of pneumonia in the elderly

Pharmacoepidemiology and Drug Safety

Volumn 24, Issue 12, 2015, Pages 1271-1280

  Mehta, Sandhya ^a   Pulungan, Zulkarnain ^b   Jones, Barton T ^b   Teigland, Christie ^b  

^a IQVIA   (United States)

^b Inovalon Inc   (United States)

Author keywords

atypical antipsychotics; comparative; elderly; multiple propensity scores; pharmacoepidemiology; pneumonia; risk; safety; second generation

Indexed keywords

ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

AGED; ARTICLE; DRUG EFFECT; DRUG EXPOSURE; DRUG SAFETY; DRUG USE; FEMALE; FOLLOW UP; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PNEUMONIA; POPULATION RESEARCH; PRIORITY JOURNAL; PROPENSITY SCORE; RISK ASSESSMENT;

EID: 84977663122     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.3882     Document Type: Article

References (33)

1. Jano E, Chen H, Johnson ML, et al. Antipsychotic utilization and expenditure trends among elderly persons. Psychiatr Serv 2007; 58(11): 1400.
2. Leucht S, Barnes TR, Kissling W, et al. Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials. Am J Psychiatry 2003; 160: 1209–1222.
3. Alexopoulos GS, Streim J, Carpenter D, Docherty JP. Expert consensus panel for using antipsychotic drugs in older patients. Using antipsychotic agents in older patients. J Clin Psychiatr 2004; 65(Suppl 2): 5–99.
4. Jano E, Chen H, Johnson ML, et al. Antipsychotic utilization and expenditure trends among elderly persons. Psychiatr Serv 2007 Nov; 58(11): 1400.
5. Kamble P, Chen H, Sherer J, Aparasu RR. Antipsychotic drug use among elderly nursing home residents in the United States. Am J Geriatr Pharmacother 2008; 6(4): 187–97.
6. Trifiro G, Spina E, Gambassi G. Use of antipsychotics in elderly patients with dementia: do atypical and conventional agents have a similar safety profile? Pharmacol Res 2009; 59: 1–12.
7. U.S. Food and Drug Administration, ed. Public health advisory: deaths with antipsychotics in elderly patients with behavioral disturbances. Silver Spring, MD: Available at: http://www.fda.gov/drugs/drugsafety/postmarketdrugsafetyinformationforpatientsandproviders/ucm053171 [3 Feb 2015]
8. U.S. Food and Drug Administration: FDA requests boxed warnings on older class of antipsychotic drugs [news release]. Silver Spring, MD: U.S. Food and Drug Administration; 16 June 2008. Available at www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2008/ucm116912.htm. [3 Feb 2015]
9. Kuo CJ, Yang SY, Liao YT, et al. Second-generation antipsychotic medications and risk of pneumonia in schizophrenia. Schizophr Bull 2013: 39(3): 648–57.
10. Trifiro G. Antipsychotic drug use and community-acquired pneumonia. Curr Infect Dis Rep 2011; 13: 262–268.
11. Trifiro G, Gambassi G, Sen EF, et al. Association of community-acquired pneumonia with antipsychotic drug use in elderly patients. Ann Intern Med 2010; 152: 418–425.
12. Aparasu RR, Chatterjee S, Chen H. Risk of pneumonia in elderly nursing home residents using typical versus atypical antipsychotics. Ann Pharmacother 2013; 47: 464–74.
13. Knol W, Van Marum RJ, Jansen PAF, et al. Antipsychotic drug use and risk of pneumonia in elderly people. J Am Geriatr Soc 2008; 56: 661–666.
14. Pratt N, Roughead EE, Ramsay E, et al. Risk of hospitalization for hip fracture and pneumonia associated with antipsychotic prescribing in the elderly—a self-controlled case-series analysis in an Australian Health Care Database. Drug Saf 2011; 34(7): 568–575.
15. Huybrechts KF, Rothman KJ, Silliman RA, et al. Risk of death and hospital admission for major medical events after initiation of psychotropic medications in older adults admitted to nursing homes. Can Med Assoc J 2011; 183(7): E411–E419.
16. Gau JT, Acharya U, Khan S, et al. Pharmacotherapy and the risk for community-acquired pneumonia. BMC Geriatr 2010; 10: 45.
17. Abdelmawla N. Clozapine and risk of pneumonia. Br J Psychiatry 2009; 194: 468–469.
18. Star K, Bate A, Meyboom RHB, et al. Pneumonia following antipsychotic prescriptions in electronic health records: a patient safety concern? Br J Gen Pract 2010; 60(579): e385–e394.
19. Trifiro G, Sultana J, Spina E. Are the safety profiles of antipsychotic drugs used in dementia the same? An updated review of observational studies. Drug Saf 2014; 37: 501–520.
20. Gambassi G, Sulatana J, Trifiro G. Antipsychotic use in elderly patients and the risk of pneumonia. Expert Opin Drug Saf 2015; 14(1): 1–6.
21. Barnett MJ, Perry PJ, Alexander B, et al. Risk of mortality associated with antipsychotic and other neuropsychiatric drugs in pneumonia patients. J Clin Psychopharmacol 2006; 26: 182–7.
22. Wang PS, Schneeweiss S, Setoguchi S, et al. Ventricular arrhythmias and cerebrovascular events in the elderly using conventional and atypical antipsychotic medications. J Clin Psychopharmacol 2007; 27: 707–10.
23. Roth BL, Meltzer HY, Khan N. Binding of typical and atypical antipsychotic drugs to multiple neurotransmitter receptors. Adv Pharmacol 1998; 42: 482–5.
24. Huybrechts KF, Schneeweiss S, Gerhard T, et al. Comparative safety of antipsychotic medications in nursing home residents. J Am Geriatr Soc 2012; 60: 420–429.
25. Guidance regarding methods for de-identification of protected health information in accordance with the Health Insurance Portability and Accountability Act (HIPAA) privacy rule. Washington, DC: U.S. Department of Health & Human Services n.d. Available at: http://www.hhs.gov/ocr/privacy/hipaa/understanding/coveredentities/De-identification/guidance.html (25 September 2014)
26. Chatterjee S, Chen H, Johnson ML, et al. Comparative risk of cerebrovascular adverse events in community-dwelling older adults using risperidone, olanzapine and quetiapine. Drugs Aging 2012; 29: 807–817.
27. Braitman LE, Rosenbaum PR. Rare outcomes, common treatments: analytic strategies using propensity-scores. Ann Intern Med 2002; 137: 693–695.
28. Spreeuwenberg MD, Bartak A, Croon MA, et al. The multiple propensity-score as control for bias in the comparison of more than two treatment arms—an introduction from a case study in mental health. Med Care 2010; 48: 166–174.
29. Leucht S, Pitschel-Walz G, Abraham D, et al. Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophr Res 1999; 35(1): 51–68.
30. Yang SY, Kao Yang YH, Chong MY, et al. Risk of extrapyramidal syndrome in schizophrenic patients treated with antipsychotics: a population-based study. Clin Pharmacol Ther 2007; 81: 586–594.
31. Eland IA, Huerta Alvarez C, Stricker BHCH, et al. The risk of acute pancreatitis associated with acid-suppressing drugs. Br J Clin Pharmacol 2000; 49: 473–478.
32. Roth B. NIH Psychoactive Drug Screening Program. Ki Database. Available at: https://pdspdb.unc.edu/pdspWeb/ (21 June 2015)
33. Cornell CU. From receptor pharmacology to improved outcomes: individualizing the selection, dosing, and switching of antipsychotics. Eur Psychiatry 2010; 25: S12–S21.